Navigation Links
Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs
Date:2/11/2010

PARSIPPANY, N.J., Feb. 11 /PRNewswire-FirstCall/ -- Daiichi Sankyo, Inc. (DSI) announced today that Jay M. Feingold, M.D., Ph.D., has been appointed Vice President of Medical Affairs. Dr. Feingold will manage strategic direction of the company's Medical Affairs department and oversee more than 90 scientists, researchers and field-based medical teams responsible for collaborating with the company's clinical research arm, commercial organization and partners. Medical Affairs is responsible for providing physicians, key opinion leaders, regulatory agencies and professional organizations with medical and scientific information in the areas of clinical studies, outcomes research and disease management programs, among others. Dr. Feingold's vast experience in oncology and hematology will continue to drive the company's current cardiovascular portfolio and shape its pipeline.

"I am very excited to join Daiichi Sankyo and look forward to working with my colleagues to continue to build relationships with health care providers to improve medical care and enhance professional education," said Dr. Feingold. "As we develop new and innovative therapies it will be important to ensure that critical safety and efficacy information is understood by practitioners, regulatory agencies, payors and patients. Medical Affairs plays a key role in communicating this information."

Dr. Feingold also becomes a member of DSI's Executive Committee, which is responsible for guiding the organization's short- and long-term strategic and financial objectives.

DSI is the U.S. subsidiary of Tokyo-based Daiichi Sankyo Co., Ltd. The U.S. headquarters facility in Parsippany, New Jersey houses 480 employees, including corporate offices and all functions that support the company's
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
2. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
3. Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
4. Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG
5. Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation
6. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
7. KGI Names Kerry Howell Vice President for Advancement
8. Vical Names Andrew de Guttadauro Vice President, Corporate Development
9. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
10. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
11. CryoLife Names Philip Theodore as Vice President, General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that the Company closed ... Oracle Investment Management, Jack W. Schuler , ... proceeds were $10.5 million, before offering expenses.  The ... general corporate purposes. Under the terms ...
(Date:12/24/2014)... 23, 2014 SoundConnect’s ... designed to introduce cutting edge communication technology, ... partners of platform upgrades. This webinar series ... users in their quest to leverage web ... According to SoundConnect’s Marketing Manager, Seanna Baumgartner, ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 The report ... at 19.7% by 2019. It also provides a carefully ... strategies and challenges for the market. , Full Copy ... the report, the global market for cell expansion will ... future. It expects this growth to be driven by ...
(Date:12/24/2014)... 2014 Sigma-Aldrich Corporation (NASDAQ: ... under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) ... 22, 2014, thereby completing the U.S. HSR Act ... of the Company by Merck KGaA, Darmstadt, Germany.  ... condition to closing the transaction, which remains subject ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3
... /PRNewswire/ - IntelliPharmaCeutics Ltd. (Delaware),is pleased to ... pilot,clinical trial for its new abuse-resistant, alcohol-resistant ... IntelliPharmaCeutics,Corp. of Toronto ("IntelliPharmaCeutics" or the "Company"). ... for its novel ReXista(TM) abuse and,alcohol resistant ...
... International,Corporation ("PAREXEL") (Nasdaq: PRXL ) today announced ... the clinical pharmacology business of,Synchron Research in Ahmedabad, ... bioanalytical laboratory in Poitiers, France to a subsidiary ... of the new agreement, PAREXEL,s ownership interest in,the ...
... Core Informatics announces,that it has completed a ... System (LIMS) product, the "Core LIMS",for Progenics ... biopharmaceutical,company located in Tarrytown, NY. As part ... from its previous data management system.,The newly ...
Cached Biology Technology:IntelliPharmaCeutics Announces Successful Completion of a Pilot Clinical Trial for its Abuse and Alcohol Resistant Sustained Release Oxycodone 2IntelliPharmaCeutics Announces Successful Completion of a Pilot Clinical Trial for its Abuse and Alcohol Resistant Sustained Release Oxycodone 3PAREXEL International Expands Relationship with Synchron Research in India and Divests Bioanalytical Laboratory in France 2PAREXEL International Expands Relationship with Synchron Research in India and Divests Bioanalytical Laboratory in France 3PAREXEL International Expands Relationship with Synchron Research in India and Divests Bioanalytical Laboratory in France 4
(Date:12/10/2014)... RALEIGH, N.C. , Dec. 9, 2014  Valencell, ... announced it is seeing a staggering demand from its ... demand, the Company revealed, is not solely coming from ... industries as well. "A wearable is only ... a result, accuracy is the ultimate driver in long-term ...
(Date:12/10/2014)... , Dec. 9, 2014 CIE San ... catalyst that provides the connective tissue that enhances care ... them to easily share client-level information; earned a second ... expand to organizations serving seniors aging in community and; ... partner on December 11 th 4-6p. ...
(Date:12/10/2014)... December 9, 2014   ... Platform   Jifflenow, ... scheduling solutions for business-to-business (B2B) events, today announced ... in mobile near-field communication (NFC), Bluetooth low energy ... (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... has found that three commonly used herbicides can ... at possible effects on the Lange,s metalmark, an ... implications for other at-risk and endangered butterflies wherever ... and director of the WSU Puyallup Research and ...
... of Standards and Technology (NIST) has released a new ... Resources Damage Assessment (NRDA) in the wake of the ... the Louisiana coast. The new Standard Reference Material, Gulf ... as a quality control material for the ongoing environmental ...
... available in German . Sperm have only ... in their quest by emitting attractants. Calcium ions determine the beating ... Together with colleagues from the Max Planck Institute for the Physics ... from the caesar research centre in Bonn, an institute of the ...
Cached Biology News:Commonly used herbicides seen as threat to endangered butterflies 2NIST releases Gulf of Mexico crude oil reference material 2Sperm can count 2
... represents the state-of-the-art in permanent mounting ... permanent preservation of immunohistochemical organic insoluble ... Red, New Fuchsin, and any other ... tissue sections. Clarin can be used ...
... pLivSelect is a direct ... recombinant identification. Recombinant selection ... survival, eliminating the need ... This quick and inexpensive ...
... Express is the first fully automated proteomics ... transfer operations with complete data tracking. It ... colony picking through final protein expression and ... of delivering a plate to any of ...
... OLIGO is a multi-functional program ... oligonucleotides from a sequence file ... DNA sequencing, site-directed mutagenesis, and ... hybridization temperature and secondary structure ...
Biology Products: